Effects of Turmeric on inflammatory factors affecting Remodeling after acute myocardial infarction

Effects of Turmeric (Curcumin) on inflammatory factors affecting Remodeling after acute ST-segment elevation myocardial infarction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012112011235N1

Enrollment

Registered

2013-01-08

Start date

2013-01-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute transmural myocardial infarction of unspecified site. Transmural myocardial infarction NOS

Interventions

Capsule placebo three times daily for 4 weeks

Curumin 250 mg orally three times daily (750 mg) for 4 weeks

Intervention 1: Capsule placebo three times daily for 4 weeks. Intervention 2: Curumin 250 mg orally three times daily (750 mg) for 4 weeks.

Treatment - Drugs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with ST-segment elevation myocardial infarction exclusion criteria: Acute or chronic infection; co-exciting autoimmune diseases such as connective tissue disorders; malignancy; surgery during one month ago; treatment with corticosteroids, immunosuppressants, thiazolidinediones, or NSAIDs; chronic liver disease; chronic renal disease (serum creatinine more than 3 mg/dl or glomerular filtration rate less than ml/min)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CTnT. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/L).;CKMB. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Interleukin 1. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Interleukin 6. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Tumor necrosis factor-alpha. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;N-terminal prohormone of brain natriuretic peptide. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;C-reactive protein. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).	—

Measure

Time frame

CTnT. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/L).;CKMB. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Interleukin 1. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Interleukin 6. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;Tumor necrosis factor-alpha. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;N-terminal prohormone of brain natriuretic peptide. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).;C-reactive protein. Timepoint: before intervention, 8 weeks later. Method of measurement: Laboratory Test (ng/ml).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Javad Alemzadeh-Ansari

Tehran Heart Center Hospital

mj.aansari@gmail.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026